TherapeuticsMD (NASDAQ:TXMD) & SciSparc (NASDAQ:SPRC) Critical Analysis

TherapeuticsMD (NASDAQ:TXMD) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for TherapeuticsMD and SciSparc, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
SciSparc	1	0	0	0	1.00

Risk & Volatility

TherapeuticsMD has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500.

Earnings & Valuation

This table compares TherapeuticsMD and SciSparc”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.35 million	6.90	-$570,000.00	$0.06	33.33
SciSparc	$860,000.00	4.59	-$12.18 million	N/A	N/A

TherapeuticsMD has higher revenue and earnings than SciSparc.

Profitability

This table compares TherapeuticsMD and SciSparc’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
SciSparc	N/A	N/A	N/A

Summary

TherapeuticsMD beats SciSparc on 8 of the 9 factors compared between the two stocks.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.